Substudy of MEET-OS (NCT04948632): Monitoring of Patients After Ambulatory Surgery by Biobeat® Devices
- Conditions
- Patient ComplianceSurgery-ComplicationsPatient Satisfaction
- Registration Number
- NCT05686109
- Lead Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Brief Summary
The objective of this ancillary study of the MEET-OS study is to assess the technical feasibility of using Biobeat® monitoring devices after ambulatory surgery at high risk of complications.
The secondary objectives are to assess: i) the patient's experience and tolerance ii) the occurrence of clinical disturbances in the patients's home after ambulatory surgery with high risk of postoperative complications iii) to determine the impact of the data obtained with the monitoring devices on the clinical care decisions during postoperative follow-up.
- Detailed Description
With increasingly complex surgeries and increasingly comorbid patients, ambulatory surgery are not always at low risk of postoperative complications. Among the new support tools available for monitoring patients remotely, devices for monitoring vital signs could be of interest to healthcare staff in charge of monitoring, more precisely when comorbid patients are involved or when interventions at high risk of complications are performed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
- Patients over 18 years old undergoing elective outpatient surgery under general or regional anesthesia
- Internet access for the patient or their caregiver from home
- Written, oral and spoken comprehension of French
- Considered to be at high risk of postoperative complications, defined by one of the following two criteria: an ASA 3 score or an ASA score of 2 + surgery at intermediate or high risk according to the classification of Glance and al.
- Patient's or caregiver's inability to learn and to use digital technologies
- Conversion of ambulatory to inpatient hospitalization on the day of surgery
- Patient's refusal
- Operation performed under regional or neuraxial anesthesia alone
- Trophic skin disorders contraindicating the installation of the Biobeat® monitoring device on the torso (deformation, irritation, infection, ulceration, etc.)
- Patient with pacemaker
- MRI or CT scheduled post-operatively
- Tattoo on the torso or refusal to shave the area where the Biobeat® monitoring device should be installed
- Pregnant or breastfeeding women
- Allergy to one of the technological components
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with no loss of data for a period of 2 consecutive hours over the entire follow-up period. From the installation of the monitoring device after the surgery up to 5 days postoperatively.
- Secondary Outcome Measures
Name Time Method Percentage of patients with no data loss for 1, 4, 6, and 8 consecutive hours over the entire follow-up period. From the installation of the monitoring device after the surgery up to 5 days postoperatively. Percentage of patients with data loss of one hour or more preceding a postoperative event. From the installation of the monitoring device after the surgery up to 5 days postoperatively. The postoperative event is defined as a call to the CHUM health info line.
Frequency of occurrences and the cumulative time of clinical disturbances From the installation of the monitoring device after the surgery up to 5 days postoperatively. The occurrence of manufacturer alerts and the following clinical disturbances within 72 hours postoperatively will be evaluated: moderate postoperative arterial hypotension (defined by mean arterial pressure \< 65 mmHg), severe arterial hypotension defined by MAP \< 60 mmHg; moderate arterial hypertension defined by an MAP \> 110mmHg; severe arterial hypertension defined by a MAP \> 130mmHg; bradycardia defined by a heart rate \< 40bpm; tachycardia defined by a heart rate \> 100bpm; bradypnea defined by respiratory rate \< 8/min; tachypnea defined by respiratory rate \> 20/min; oxygen desaturation \< 95%; oxygen desaturation \< 90%; oxygen desaturation \< 85%; hypothermia defined as body temperature \< 36.0°C; hyperthermia defined as body temperature \> 38.0°C.
Percentage of appropriate and inappropriate clinical decision changes from the clinical intervention decided by the expert committee will be assessed. Up to 60 days after surgery Percentage of useful data available per day for the interpretation of vital signs during the first 5 days From the installation of the monitoring device after the surgery up to 5 days postoperatively. Patient's experience 7 days after the surgery A phone interview will be conducted to collect the patient's experience with a questionnaire derived from Breteler and al., which consist of 12 questions, adapted to the present study and focused on the experience of the patient and his caregiver, his tolerance and his satisfaction.
Trial Locations
- Locations (1)
Centre Hospitalier de l'Université de Montréal (CHUM)
🇨🇦Montréal, Quebec, Canada